Alicon Pharmaceutical Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 20-06-2024
- Paid Up Capital ₹ 7.50 M
as on 20-06-2024
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 95.00 M
as on 20-06-2024
- Satisfied Charges ₹ 78.43 M
as on 20-06-2024
- Revenue -33.39%
(FY 2023)
- Profit -45.70%
(FY 2023)
- Ebitda -33.25%
(FY 2023)
- Net Worth 15.47%
(FY 2023)
- Total Assets 19.67%
(FY 2023)
About Alicon Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹9.50 Cr. The company has closed loans amounting to ₹7.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mayuri Savani, Chandan Soni, Nitinbhai Savani, and Three other members serve as directors at the Company.
- CIN/LLPIN
U99999MH1995PTC086137
- Company No.
086137
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Mar 1995
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Palghar, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Alicon Pharmaceutical?
Board Members(6)
Financial Performance and Corporate Structure Insights of Alicon Pharmaceutical.
Alicon Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 33.39% decrease. The company also saw a substantial fall in profitability, with a 45.7% decrease in profit. The company's net worth Soared by an impressive increase of 15.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alicon Pharmaceutical?
In 2023, Alicon Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tapadiya Interventional Technologies & H Ealthcare Llp
Active
7 years 8 months Anup Tapadiya is a mutual person
Satvam Pharma Private Limited
Active 4 years 9 months Chandan Soni, Priyank Savani and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Sep 2019 | ₹5.00 M | Open |
Others Creation Date: 20 Dec 2018 | ₹5.00 Cr | Open |
Others Creation Date: 20 Dec 2018 | ₹4.00 Cr | Open |
How Many Employees Work at Alicon Pharmaceutical?
Alicon Pharmaceutical has a workforce of 40 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Dec 08, 2010, Alicon Pharmaceutical has raised a total of ₹ 1.08 M, with the most recent deal valued at ₹ 0.54 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
